Philip Zimmermann

Philip Zimmermann is the CEO of Prevision Medicine, a spin-off from ETH Zürich focused on providing personalized cancer treatment analyses using an AI-driven approach. His company aims to simplify and expedite the process of analyzing patient samples, delivering rapid reports that rank medications based on their effectiveness for individual patients, thus fostering greater accessibility to personalized cancer treatment options.